<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02053038</url>
  </required_header>
  <id_info>
    <org_study_id>13SM1797</org_study_id>
    <nct_id>NCT02053038</nct_id>
  </id_info>
  <brief_title>Functional Lesion Assessment of Intermediate Stenosis to Guide Revascularisation</brief_title>
  <acronym>DEFINE-FLAIR</acronym>
  <official_title>Prospective, Multi-center, Double Blind, Randomised Study to Test the Safety of Deferral of Stenting in Physiological Non-significant Lesions in a Clinical Population of Intermediate Stenoses Using iFR and FFR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Narrowing of coronary arteries interferes with blood flow and can cause chest pain. But
      patients may have more than one narrowing and studies have shown that not all narrowings need
      to be treated. To identify the narrowings that need treating cardiologists sometimes quantify
      the extent of the narrowing by measuring fractional flow reserve (FFR, the ratio of the
      pressure in the aorta to the pressure downstream of the narrowing).This technique requires
      the administration of drugs that add cost and time to the procedure and in some countries are
      simply unavailable. As a result despite the clear health and healthcare costs benefits of FFR
      its use is limited to less than 5% of procedure. We have developed a new technique called the
      instantaneous wave-free ratio (iFR) that does not require the administration of drugs for its
      accurate assessment. It has been approved for use in this indication. This study aims to
      compare clinical outcomes of patients whose treatment has been guided by iFR to those whose
      treatment has been guided by FFR. If iFR is found to provide the same clinical outcomes as
      FFR its adoption will permit the clear benefits of this approach of identifying the coronary
      narrowings that really need treatment to be applicable to a much larger patient population
      and further improve healthcare costs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design:

      Patients with one or more coronary stenoses, in which the physiological severity from
      coronary angiography is in question, will be randomised 1:1 to use of the instantaneous wave
      free ratio (iFR) or fractional flow reserve (FFR) to guide the treatment strategy for
      percutaneous coronary intervention (PCI).

      Aims:

      To assess whether the iFR is non-inferior to FFR when used to guide treatment of coronary
      stenosis with PCI.

      Outcome measures:

      The primary endpoint will be major adverse cardiac event rate in the iFR and FFR groups at 30
      days, 1, 2, and 5 years.

      Population:

      This will be an international multi-centre study of 2500 patients. From population estimates,
      35% of the total study population will present with stable angina and 65% will have acute
      coronary syndrome.

      Eligibility:

      Patients will be eligible when the physiological severity of a stenosis within a vessel is in
      question. In the cases of stable angina this will be confined to the target vessel, or with
      acute coronary syndrome assessment this will be made in the non-culprit vessel.

      Duration:

      Anticipated recruitment is 12 months. Follow-up will be performed at 30 days, 1, 2 and 5
      years.

      Results:

      Primary outcome results will be reported in Spring 2017.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 19, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 19, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiac Events</measure>
    <time_frame>30 days, 1, 2 and 5 years</time_frame>
    <description>Composite of death, myocardial infarction, unplanned revascularisation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death (all cause)</measure>
    <time_frame>30 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death (cardiovascular)</measure>
    <time_frame>30 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>30 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeat revascularisation</measure>
    <time_frame>30 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost associated to iFR or FFR measurement</measure>
    <time_frame>30 days, 1, 2 and 5 years</time_frame>
    <description>Cost associated to iFR or FFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>30 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost savings of removing secondary investigations</measure>
    <time_frame>30 days, 1, 2 and 5 years</time_frame>
    <description>7) Cost savings of removing secondary investigations, by assessing/treating non-culprit acute coronary syndrome (ACS) at the time of index presentation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>iFR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment guided by iFR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FFR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment guided by FFR</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iFR</intervention_name>
    <description>Treatment guided by instantaneous wave-free ratio</description>
    <arm_group_label>iFR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FFR</intervention_name>
    <description>Treatment guided by Fractional Flow Reserve</description>
    <arm_group_label>FFR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 18 years of age

          2. Willing to participate and able to understand, read and sign the informed consent
             document before the planned procedure

          3. Eligible for coronary angiography and/or percutaneous coronary intervention

          4. Coronary artery disease with at least 1 or more native major epicardial vessels or
             their branches by coronary angiogram with visually assessed de novo coronary stenosis
             in which the physiological severity of the lesion is in question (typically 40-70%
             diameter stenosis).

          5. Stable angina or acute coronary syndrome (non-culprit vessels only and outside of
             primary intervention during acute STEMI)

        Exclusion criteria:

          1. Previous Coronary Artery Bypass surgery with patent grafts to the interrogated vessel

          2. Significant left main stenosis (&gt;50% narrowing)

          3. Tandem stenoses separated by more than 10 mm that require separate pressure guide wire
             interrogation or percutaneous coronary intervention (PCI) (not to be interrogated or
             treated as a single stenosis)

          4. Total coronary occlusions (CTOs). NOTE: Patients with CTOs can be included if i)
             treatment of the CTO is completed first, ii) the CTO PCI is successful, iii) the CTO
             PCI is successful and iii) the physiological lesion is in another vessel

          5. Restenotic lesions

          6. Hemodynamic instability at the time of intervention (heart rate&lt;50 beats per minute,
             systolic blood pressure &lt;90mmHg), balloon pump

          7. Significant contraindication to adenosine administration (e.g. heart block, severe
             asthma)

          8. Contraindications to PCI (percutaneous coronary intervention) or drug-eluting stent
             (DES) implantation

          9. Heavily calcified or tortuous vessels

         10. Significant hepatic or lung disease (chronic pulmonary obstructive disease), and/or
             malignant disease with unfavourable prognosis that may influence survival within the
             next 5 years

         11. Pregnancy

         12. STEMI (ST elevation myocardial infarction) within 48 hours of procedure

         13. Severe valvular heart disease

         14. ACS patients in whom more than one target vessel is present
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Justin ER Davies, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Escaned, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinico San Carlos</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Serruys, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manesh Patel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sayan Sen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arnold Seto</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Altman</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Habib Samady</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allen Jeremias</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manesh Patel</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sam Lehman</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Darren Walters</name>
      <address>
        <city>Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Sapontis</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ravinay Bhindi</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian Vrints</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luc Janssens</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ahmed Khashaba</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mika Laine</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florian Krackhardt</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olaf Going</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waldemar Bojara</name>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tobias Haerle</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ciro Indolfi</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Giampaolo Nicolli</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flavio Ribichini</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroaki Takashima</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroyoshi Yokoi</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yuetsu Kikuta</name>
      <address>
        <city>Fukuyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hitosh Matsuo</name>
      <address>
        <city>Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nob Tanaka</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang-Wook Nam</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joon-Hyung Doh</name>
      <address>
        <city>Daehwa</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bon-Kwon Koo</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eun-Seok Shin</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andrejs Erglis</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jan Piek</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niels Van Royen</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martijn Meuwissen</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hugo Vinhas</name>
      <address>
        <city>Almada</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sergio Baptista</name>
      <address>
        <city>Amadora</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pedro Canas Silva</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ali Alghamadi</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Farrel Hellig</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salvatore Brugaletta</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eduardo Alegria</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Murat Sezer</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kare Tang</name>
      <address>
        <city>Basildon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suneel Talwar</name>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andrew Sharp</name>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ranil De Silva</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rajesh Kharbanda</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Gerber</name>
      <address>
        <city>St Leonards</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Egypt</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Saudi Arabia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2013</study_first_submitted>
  <study_first_submitted_qc>January 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2014</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

